Literature DB >> 17485711

Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.

Anthony Lucci1, Linda Mackie McCall, Peter D Beitsch, Patrick W Whitworth, Douglas S Reintgen, Peter W Blumencranz, A Marilyn Leitch, Sukumal Saha, Kelly K Hunt, Armando E Giuliano.   

Abstract

PURPOSE: The American College of Surgeons Oncology Group trial Z0011 was a prospective, randomized, multicenter trial comparing overall survival between patients with positive sentinel lymph nodes (SLNs) who did and did not undergo axillary lymph node dissection (ALND). The current study compares complications associated with SLN dissection (SLND) plus ALND, versus SLND alone. PATIENTS AND METHODS: From May 1999 to December 2004, 891 patients were randomly assigned to SLND + ALND (n = 445) or SLND alone (n = 446). Information on wound infection, axillary seroma, paresthesia, brachial plexus injury (BPI), and lymphedema was available for 821 patients.
RESULTS: Adverse surgical effects were reported in 70% (278 of 399) of patients after SLND + ALND and 25% (103 of 411) after SLND alone (P <or= .001). Patients in the SLND + ALND group had more wound infections (P <or= .0016), seromas (P <or= .0001), and paresthesias (P <or= .0001) than those in the SLND-alone group. At 1 year, lymphedema was reported subjectively by 13% (37 of 288) of patients after SLND + ALND and 2% (six of 268) after SLND alone (P <or= .0001). The difference between the two groups' lymphedema, assessed by arm measurements at 30 days (P = .36), 6 months (P = .22), and 1 year (P = .078), although close to the cutoff for significance at 1 year, was not significant. BPIs occurred in less than 1% of patients.
CONCLUSION: In trial Z0011, the use of SLND + ALND resulted in more wound infections, axillary seromas, and paresthesias than SLND alone. Lymphedema was more common after SLND + ALND but was significantly different only by subjective report. The use of SLND alone resulted in fewer complications.

Entities:  

Mesh:

Year:  2007        PMID: 17485711     DOI: 10.1200/JCO.2006.07.4062

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  208 in total

1.  Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node.

Authors:  Elizabeth A Mittendorf; Kelly K Hunt; Judy C Boughey; Roland Bassett; Amy C Degnim; Robyn Harrell; Min Yi; Funda Meric-Bernstam; Merrick I Ross; Gildy V Babiera; Henry M Kuerer; Rosa F Hwang
Journal:  Ann Surg       Date:  2012-01       Impact factor: 12.969

2.  Prospective surveillance of breast cancer-related lymphoedema in the first-year post-surgery: feasibility and comparison of screening measures.

Authors:  J M Blaney; G McCollum; J Lorimer; J Bradley; R Kennedy; J P Rankin
Journal:  Support Care Cancer       Date:  2014-11-16       Impact factor: 3.603

Review 3.  Update in women's health for the general internist.

Authors:  Judith M E Walsh; Megan McNamara; Redonda G Miller; Eleanor Bimla Schwarz
Journal:  J Gen Intern Med       Date:  2011-10-13       Impact factor: 5.128

4.  Risk factors for lymphedema in a prospective breast cancer survivorship study: the Pathways Study.

Authors:  Marilyn L Kwan; Jeanne Darbinian; Kathryn H Schmitz; Rebecca Citron; Paula Partee; Susan E Kutner; Lawrence H Kushi
Journal:  Arch Surg       Date:  2010-11

5.  A grid matrix-based Raman spectroscopic method to characterize different cell milieu in biopsied axillary sentinel lymph nodes of breast cancer patients.

Authors:  Dipasree Som; Megha Tak; Mohit Setia; Asawari Patil; Amit Sengupta; C Murali Krishna Chilakapati; Anurag Srivastava; Vani Parmar; Nita Nair; Rajiv Sarin; R Badwe
Journal:  Lasers Med Sci       Date:  2015-11-09       Impact factor: 3.161

6.  Omission of Axillary Lymph Node Dissection is Associated with Inferior Survival in Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy.

Authors:  Muayad F Almahariq; Ronald Levitin; Thomas J Quinn; Peter Y Chen; Nayana Dekhne; Sayee Kiran; Amita Desai; Pamela Benitez; Maha S Jawad; Gregory S Gustafson; Joshua T Dilworth
Journal:  Ann Surg Oncol       Date:  2020-07-25       Impact factor: 5.344

7.  Axillary lymph node management in breast cancer with positive sentinel lymph node biopsy.

Authors:  Ioannis A Voutsadakis; Silvana Spadafora
Journal:  World J Clin Oncol       Date:  2015-02-10

Review 8.  Management of the Axilla after Neoadjuvant Systemic Therapy.

Authors:  Trista J Stankowski-Drengler; Heather B Neuman
Journal:  Curr Treat Options Oncol       Date:  2020-05-27

9.  Sentinel lymph node biopsy in early-stage breast cancer patients: improved survival through better staging?

Authors:  Pamela Meiers; Tulin Cil; Ulrich Guller; Markus Zuber
Journal:  Langenbecks Arch Surg       Date:  2012-12-11       Impact factor: 3.445

10.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.

Authors:  Viviana Galimberti; Bernard F Cole; Stefano Zurrida; Giuseppe Viale; Alberto Luini; Paolo Veronesi; Paola Baratella; Camelia Chifu; Manuela Sargenti; Mattia Intra; Oreste Gentilini; Mauro G Mastropasqua; Giovanni Mazzarol; Samuele Massarut; Jean-Rémi Garbay; Janez Zgajnar; Hanne Galatius; Angelo Recalcati; David Littlejohn; Monika Bamert; Marco Colleoni; Karen N Price; Meredith M Regan; Aron Goldhirsch; Alan S Coates; Richard D Gelber; Umberto Veronesi
Journal:  Lancet Oncol       Date:  2013-03-11       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.